	US 11,883,418 B2
	Compound TSYI-ZAC for inhibiting dengue virus infection and medicinal use thereof
Chia-Chang Chen, Taichung (TW); Guey-Chuen Perng, Tainan (TW); Hsiu-Man Lien, Taichung (TW); and Yi-Ju Chen, Taichung (TW)
Assigned to SYI BIOTECHNOLOGY CO., LTD., Taichung (TW)
Filed by Syi Biotechnology Co., Ltd., Taichung (TW)
Filed on Jun. 8, 2022, as Appl. No. 17/835,221.
Claims priority of application No. 111108474 (TW), filed on Mar. 9, 2022.
Prior Publication US 2023/0285415 A1, Sep. 14, 2023
Int. Cl. A61K 31/575 (2006.01); A61K 31/357 (2006.01); A61P 31/20 (2006.01)

CPC A61K 31/575 (2013.01) [A61K 31/357 (2013.01); A61P 31/20 (2018.01)]

8 Claims

1. A method for treating dengue virus infection, comprising administrating an effective amount of a pharmaceutical composition comprising compound TSYI-ZAC and 4,7-dimethoxy-5-methyl-1,3-benzodioxole to a subject in need of, wherein the compound TSYI-ZAC is a Zhankuic acid C compound, a dose of the compound TSYI-ZAC is 5 μg/mL to 100 μg/mL, and a dose of 4,7-dimethoxy-5-methyl-1,3-benzodioxole compound is 5 μg/mL to 200 μg/mL.